Study of Danicopan in Participants With Hepatic Impairment

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACH-0144471 (danicopan) in participants with hepatic impairment (HI) as compared to healthy matched participants.

Key facts

Study ID

NCT03555539

Run by

Alexion Pharmaceuticals, Inc.

People needed

16

Starts

2018-05-01

Expected to finish

2018-09-21

Last updated by the study team

2021-08-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• Clinical Trial Site — Miami, Florida, United States
• Clinical Trial Site — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.